uniQure Reports Q3 2026 Financial Results and AMT-130 Clinical Updates
uniQure (QURE) reported third-quarter revenue of $5.2 million, an increase from $3.7 million in the prior year period driven by higher license revenue. Despite a net loss of $61.2 million ($0.88 per share), the company improved its bottom line compared to the $80.5 million loss reported in Q3 2025. The company maintains a strong liquidity position with $768.4 million in cash and investment securities, which management expects will fund operations through 2030. Clinical progress remains centered on AMT-130 for Huntington's disease, with the FDA having accepted its Biologics License Application for priority review; a PDUFA date is set for May 1, 2027. Long-term efficacy data showed significant slowing of disease progression in high-dose patients over 36 and 48 months. Additionally, the company provided updates on AMT-260 for epilepsy and resumed enrollment for its Fabry disease program (AMT-191) following the resolution of previous liver enzyme concerns.
Topics: cash runway clinical trial efficacy FDA PDUFA date revenue growth
Read the full article at Motley Fool
Part of the story InMode Reports Q3 2026 Financial Results with Stable Revenue and Reaffirmed Outlook (23 articles)